Newsbenzinga
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs
· Published
Article summary
FDA accepts Sarepta's filings seeking traditional approval for AMONDYS 45 and VYONDYS 53, with a decision expected by February 2027.
An excerpt from the original article.
Comments —
Loading comments…